Hualan Biological Engineering, Inc. News

Hualan Biological Engineering, Inc. (002007.SZ): The company has a total of 34 blood plasma collection stations (including 6 branch stations).

On April 14, Glonghui reported that Hualan Biological Engineering, Inc. (002007.SZ) stated on the investor interaction platform that the company has a total of 34 single-plasma collection stations (including 6 branch stations). In 2024, the total plasma collection volume will be 1,586.37 tons, an increase of 18.18% compared to the previous year.

Gelonghui FinanceApr 14 03:12 ET

These Analysts Just Made A Meaningful Downgrade To Their Hualan Biological Engineering Inc. (SZSE:002007) EPS Forecasts

Simply Wall StApr 4 18:53 ET

Hualan Biological Engineering Inc. Just Missed EPS By 19%: Here's What Analysts Think Will Happen Next

Simply Wall StApr 1 18:52 ET

Hualan Biology: 2024 Annual Report

SZSIMar 28 12:00 ET · Announcements

Hualan Biology: 2024 Annual Report Summary

SZSIMar 28 12:00 ET · Announcements

Hualan Biological Engineering, Inc. (002007.SZ): The net income attributable to the parent company for the year 2024 is 1.088 billion yuan, proposing a dividend of 2 yuan per share.

Gelonghui, March 28 - Hualan Biological Engineering, Inc. (002007.SZ) announced its 2024 annual report, achieving revenue of 4.379 billion yuan in 2024, a year-on-year decrease of 18.02%; net income attributable to shareholders of the listed company was 1.088 billion yuan, a year-on-year decrease of 26.57%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.981 billion yuan, a year-on-year decrease of 22.56%; the basic EPS was 0.5958 yuan; it plans to distribute a cash dividend of 2 yuan (including tax) for every 10 shares to all shareholders.

Gelonghui FinanceMar 28 05:24 ET

Express News | Hualan Biological Engineering 2024 Net Profit Down 26.6% Y/Y

ReutersMar 28 05:22 ET

Hualan Biological Engineering Inc.'s (SZSE:002007) Largest Shareholders Are Retail Investors With 39% Ownership, Private Companies Own 29%

Simply Wall StMar 20 00:00 ET

Hualan Biological Engineering Inc.'s (SZSE:002007) Low P/E No Reason For Excitement

Simply Wall StFeb 5 21:16 ET

Hualan Biological Engineering, Inc. (002007.SZ): The Chairman, the actual controller, some directors, and senior executives completed a Shareholding of a total of 1.4957 million shares.

Gelonghui, January 8th丨Hualan Biological Engineering, Inc. (002007.SZ) announced that as of January 8, 2025, the relevant shareholding plan period has expired and the plan has been fully implemented. The chairman, actual controller, some directors, and senior management personnel have collectively increased their shareholding by 1.4957 million shares, all of which are not less than their respective promised minimum shareholding quantities.

Gelonghui FinanceJan 8 04:59 ET

Hualan Biological Engineering Inc.'s (SZSE:002007) Stock Has Shown A Decent Performance: Have Financials A Role To Play?

Simply Wall StDec 29, 2024 20:30 ET

Are Investors Undervaluing Hualan Biological Engineering Inc. (SZSE:002007) By 42%?

Simply Wall StDec 12, 2024 01:06 ET

Hualan Biological Engineering, Inc. (002007.SZ): The company has obtained a single-sourced plasma collection license.

On December 4, Gelonghui reported that hualan biological engineering, inc. (002007.SZ) announced that on December 4, 2024, the company's wholly-owned subsidiary, hualan biological engineering chongqing co., ltd., received the "Plasma Collection License" issued by the Chongqing Municipal Health Committee for the hualan plasma collection station in Wushan County, Chongqing (hereinafter referred to as "Wushan Plasma Station"). The Wushan Plasma Station can officially begin plasma collection from the date it obtains the "Plasma Collection License." The operation of plasma collection at the Wushan Plasma Station will help enhance the company's supply capacity of raw plasma, which will have a positive impact on the company's long-term development.

Gelonghui FinanceDec 4, 2024 05:26 ET

Hualan Biological Engineering's Unit Gets Certificate for Cancer Drug's Registration

MT NewswiresNov 22, 2024 02:55 ET

hualan biological engineering, inc. (002007.SZ): The genetic company has received the pharmaceutical registration certificate for the Ramucirumab injection.

On November 21, 2023, Hualan Biological Engineering, Inc. (002007.SZ) announced that on November 21, 2024, its affiliated company Hualan Gene Engineering Co., Ltd. (referred to as "Gene Company") obtained the "Drug Registration Certificate" for Bevacizumab Injection issued by the National Medical Products Administration. The Gene Company has been approved for Anbeiyou (Bevacizumab Injection), which is mainly used for the treatment of advanced, metastatic, or recurrent non-small cell lung cancer, metastatic colorectal cancer, recurrent glioblastoma, hepatocellular carcinoma, epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, cervical cancer, with the original manufacturer being Roche.

Gelonghui FinanceNov 21, 2024 03:52 ET

Hualan Biological Engineering (SZSE:002007) Sheds CN¥1.8b, Company Earnings and Investor Returns Have Been Trending Downwards for Past Three Years

Simply Wall StNov 18, 2024 20:17 ET

Earnings Miss: Here's What Hualan Biological Engineering Inc. (SZSE:002007) Analysts Are Forecasting For Next Year

Simply Wall StOct 31, 2024 18:19 ET

Hualan Biological Engineering, Inc.: Third-quarter report of 2024.

SZSIOct 29, 2024 12:00 ET · Announcements

hualan biological engineering, inc. (002007.SZ) released its performance for the first three quarters, with a net income of 0.924 billion yuan, a year-on-year decrease of 13.46%.

hualan biological engineering, inc. (002007.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...

Zhitong FinanceOct 29, 2024 11:20 ET

Express News | Hualan Biological Engineering Q3 Net Profit Down 10.6% Y/Y

ReutersOct 29, 2024 06:42 ET